Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1776-260X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC ; volume:16 ; number:5 ; day:26 ; month:9 ; year:2021 ; pages:687-695 ; date:9.2021
Targeted oncology ; 16, Heft 5 (26.9.2021), 687-695, 9.2021
- Urheber
-
Lamb, Yvette N.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11523-021-00839-w
- URN
-
urn:nbn:de:101:1-2022010519044846793010
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lamb, Yvette N.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
Osimertinib (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
Osimertinib (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib